C a
2+ is a universal second messenger involved in activation/ regulation of cellular processes as diverse as neurotransmitter release, muscle contraction, metabolism, hypertrophic signaling, and cell death. To fulfill such diverse roles and yet be specific enough to trigger distinct responses, information is encoded in the amplitude, temporal properties, and subcellular localization of Ca 2+ signals. It is now largely recognized that Ca 2+ is regulated and signals differently in various subcellular microdomains. [1] [2] [3] For example, GABA (γ-aminobutyric acid receptors) inhibition in hippocampal neurons results in spatially confined inhibition of Ca 2+ transients shortly after a back-propagating action potential, which may play a key role in regulation of synaptic plasticity. 4 
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In the heart, Ca 2+ release from the sarcoplasmic reticulum (SR) is a key event for excitation-contraction coupling (ECC), ventricular arrhythmias, mitochondrial function, and nuclear transcription. 5 Cardiac SR Ca 2+ release is controlled by the local [Ca 2+ ] in the junctional cleft ([Ca 2+ ] Cleft ), the small, restricted space between the apposing sarcolemma (mostly T-tubules) and junctional SR membrane. Voltage-gated L-type Ca 2+ channels (LTCC) and Ca
2+
-activated Ca 2+ channels (or ryanodine receptors [RyRs] ) are located at these junctions in the sarcolemma and SR membrane, respectively, and are essential in this local control. [6] [7] [8] During electric excitation, [Ca 2+ ] Cleft is expected to rise higher and faster than in the bulk cytosol. [9] [10] [11] [12] Through Ca 2+ -dependent inactivation, [Ca 2+ ] Cleft feeds back on LTCC and thus plays an important role in shaping the action potential waveform. Several studies [12] [13] [14] [15] [16] [17] 
Methods
Detailed Methods are included in the Online Data Supplement.
Mutagenesis of GCaMP2-Based Ca 2+ Sensors, CleftTargeting, Plasmid Construction, and Expression in Adenoviral Vectors
The genetically encoded Ca 2+ sensors GCaMP2.2 and GCaMP2.2Low were constructed by introducing the T203V and, respectively both T203V and D133E mutations in GCaMP2. For targeting to the junctional cleft, GCaMP2.2 and GCaMP2.2Low were fused to the N terminus of FKBP12.6 through a peptide linker. The GCaMP2.2 constructs were subcloned into the pshuttleCMV vector using Bgl II and Not I restriction sites. Subsequent adenovirus generations and amplifications were done using the Adeasy system (Agilent).
Protein Expression and Purification
Tagged and untagged GCaMP2.2Low sensors were cloned into a pRSET expression vector and amplified in BL21 Star (DE3) pLysS cells, and then purified using Profinity IMAC Ni Charged Resins (Bio-Rad) and further subjected to size exclusion chromatography.
Ventricular Myocyte Isolation, Culture, and Adenoviral Infection
All animal protocols were approved by the animal welfare committee at University of California, Davis, and conform to the National Institutes of Health Publication No 85-23 (revised in 1996). Rat ventricular myocytes were isolated by digestion with collagenase, cultured in supplemented M199 media, and infected with adenoviruses expressing one of the GCaMP2.2 sensors. For some experiments, freshly isolated myocytes were permeabilized with 50 µg/mL saponin for 3 minutes. All experiments were done at room temperature.
Fluorescence Measurements
GCaMP2.2s fluorescence was recorded with a Live-5 laser scanning confocal microscope (excitation, 488 nm; emission, >505 nm). Ca 2+ transients were measured in linescan mode (2 ms/line). In other experiments, 2-dimensional images were taken 1 s apart.
Statistical Analysis
The statistical differences between groups were determined using the Student t test.
Results
Low-Affinity GCaMP-Based Genetically Encoded Ca 2+ Indicator
GCaMPs are genetically encoded Ca 2+ indicators consisting of a circularly permutated, enhanced green fluorescent protein that is flanked by calmodulin at the C terminus and by the calmodulin-binding peptide myosin light-chain kinase M13 at the N terminus ( Figure 1A ) and have been used to detect [Ca 2+ ] in vivo. [25] [26] [27] [28] The T203V mutation increases the brightness and dynamic range of GCaMP2 (GCaMP2.2), 29 and we used this as a starting point to screen mutations that decrease the Ca 2+ -binding affinity of GCaMP2.2, while maintaining brightness and dynamic range. EF-hand loop mutational screening identified GCaMP2.2Low, which contains a D133E mutation 30 in the EF-hand loop IV of calmodulin ( Figure 1A ). GCaMP2.2Low has a similar baseline fluorescence and dynamic range as GCaMP2.2, but its affinity for Ca 2+ binding is ≈10-fold lower than that of GCaMP2.2 (K d ≈5 µmol/L versus 450 nmol/L; Figure 1B Figure 1A ). FKBP12.6 is an endogenous protein that binds with high affinity (K d ≈1 nmol/L), specificity, and 1:1 stoichiometry to RyR2 monomers but does not greatly influence RyR2 function. 31 Our previous work showed that fluorescent-tagged ] Bulk , and are highly sensitive to Ca 2+ in intact myocytes. A, Example of myocytes infected with adenoviruses expressing untagged GCaMP2.2Low (left) and GCaMP2.2Low-FKBP12.6 (right). Bottom, The fluorescence profile along the longitudinal axis of the myocyte for the area shown in the white square in the top. Right and left, Limited areas from each myocyte; entire myocyte images are in Online Figure V . B, Ca 2+ -sensitivity of GCaMP2.2Low-FKBP12.6 in intact cells. A resting myocyte expressing GCaMP2.2Low-FKBP12.6 was imaged first under control conditions (Ba). The cell was then exposed to Ca 2+ -free external solution in the presence of 10 µmol/L ionomycin (Bb). This resulted in a significant fluorescence drop (F min FKBP12.6 binds in a striated pattern along T-tubules at the sites of Ca 2+ spark initiation, and that binding is prevented by preincubation with nonfluorescent FKBP12.6.
31 Linking FKBP12.6 to the GCaMP sensors does not significantly affect their Ca 2+ affinity ( Figure 1B ) or Ca 2+ -binding kinetics (Online Table I ). Saponin-permeabilized myocytes exposed to 100 nmol/L purified untagged GCaMP2.2 show uniform cytosolic distribution of the sensor (Figure 1Ca ; Online Figure I shows the entire cell). In contrast, GCaMP2.2-FKBP12.6 has a striated fluorescence pattern (Figure 1Cb ) like that seen for purified FKBP12.6 tagged with a small molecule fluorophore, 31 which suggests that the sensor is appropriately localized at the z-line where RyRs and clefts are situated. To test the specificity of GCaMP2.2-FKBP12.6 binding at RyRs further, we exposed permeabilized myocytes to GCaMP2.2-FKBP12.6 in the presence of excess nonfluorescent FKBP12.6 to saturate RyRs (Figure 1Cc ). In this case, GCaMP2.2-FKBP12.6 shows uniform cytosolic fluorescence. These data suggest that the FKBP12.6-tagged GCaMP2.2 sensors bind with high selectivity to RyRs, which are mainly cleft localized.
We next assessed the affinity of GCaMP2.2-FKBP12.6 binding to RyRs by performing sensor wash-in and washout experiments in permeabilized myocytes ( Figure 1D ). The rate constants for the dissociation (k off ) and association (k on ) of the sensor from/to RyRs were calculated from exponential fits of the decline in GCaMP2.2-FKBP12.6 fluorescence on removing the sensor from the solution (k decline =k off ), and the GCaMP2.2-FKBP12.6 fluorescence increase on addition of the sensor (k increase =k on •[GCaMP2.2-FKBP12.6]+k off ; Online Figure II) . The dissociation constant of the RyR-GCaMP2.2-FKBP12.6 complex (K d ) was calculated as k off /k on and yielded a value of 15.5±3.3 nmol/L. A similar calculation showed that GCaMP2.2Low-FKBP12.6 binds to RyRs with a K d of 43.8±6.3 nmol/L. Although these affinities are lower than previously reported for FKBP12.6 alone (≈1 nmol/L), 31 GCaMP2.2-FKBP12.6 and GCaMP2.2Low-FKBP12.6 bind RyR with relatively high affinity.
We then calibrated the [Ca 2+ ] dependence of the sensors in the myocyte environment ( Figure 1E ). The dynamic range of the sensors in myocytes was comparable with that measured in vitro (≈6-fold), but the apparent Ca 2+ affinity was slightly lower in myocytes for both GCaMP2.2-FKBP12.6 and GCaMP2.2 than in vitro (K d =1.2 and 1.3 µmol/L, respectively). GCaMP2.2Low and GCaMP2.2Low-FKBP also exhibited roughly a 2-fold decrease in apparent affinity in the myocyte environment (K d ≈11 µmol/L). Although GCaMP2.2-FKBP12.6 could increase Ca 2+ buffering in the cleft, such effect is expected to be small and have limited effect for 2 reasons. First, there would be at most 1 GCaMP per RyR, and this is minor when compared with the intense >100:1 buffering in the cleft environment. 6 After characterizing our junctional cleft-targeted Ca 2+ sensors, we expressed them in intact rat cardiac myocytes by adenoviral infection. Myocytes were used for experiments 20 to 24 hours later. Membrane staining with Di-8-ANNEPS indicated that myocytes retain the T-tubules at which most of the junctions reside, under the culture conditions (Online Figure III) . Figure IV) . There was no decrement in either the uniformity of local transverse release activation or rate of rise of the Ca 2+ transients. Thus, the clefts where the GCaMP2.2-FKBP12.6 sensors are targeted function normally during ECC.
FKBP12.6-tagged sensors express in a striated pattern, with intensity maxima spaced ≈2 µm apart (Figure 2A ; full images are shown in Online Figure V ). This strongly supports the conclusion that the FKBP12.6-tagged sensors are targeted to RyR at the z-line, as in permeabilized cells. In contrast, the untagged sensors show a rather uniform cytosolic distribution (Figure 2A) . To test the Ca 2+ responsiveness of the new sensors when expressed in intact cells, we first depleted myocytes of Ca 2+ (using ionomycin and Ca 2+ -free solution), to determine the minimum sensor fluorescence (F min ; Figure 2Bb versus Figure 2Ba) . Then, myocytes were Ca 2+ -overloaded by restoring extracellular Ca
2+
in Na + -free solution to assess maximum fluorescence (F max ) just as hypercontracture begins (Figure 2Bc) . Importantly, GCaMP2.2Low and GCaMP2.2Low-FKBP12.6 have a similar dynamic range, F max /F min, in myocytes (5.5±0.6; n=7 for GCaMP2.2 and 5.7±0.5; n=9 for GCaMP2.2-FKBP12.6). 
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These numbers agree well with those in Figure 1E . Thus, our novel FKBP12. We expressed the low-affinity untagged and FKBP12.6-tagged sensors to measure Ca 2+ transients in the bulk cytosol and junctional cleft, respectively (Figure 3 ). Myocytes were field-stimulated at 0.5 Hz, and Ca 2+ transients were measured in linescan mode using a laser scanning confocal microscope. Figure 3A shows representative Ca 2+ transients reported by GCaMP2.2Low and GCaMP2.2Low-FKBP12.6. Junctional cleft transients recorded by GCaMP2.2Low-FKBP12.6 are ≈2-fold larger ( Figure 3B ) and have a much faster upstroke (time-topeak, 46±5 versus 90±7 ms; Figure 3C ) and decay (decay τ=254±19 versus 421±42 ms; Figure 3D ) when compared with global Ca 2+ transients measured by the untargeted GCaMP2.2Low. This is encouraging (see Discussion section of this article for inferred [Ca 2+ ] values), but based on theoretical models 11 and indirect cleft Ca 2+ transient assessments, 12, 24 one would expect a much larger difference in both amplitude and kinetics between the targeted and the untargeted sensor. An obvious explanation is that the kinetics of local [Ca 2+ ] change in the cleft are likely to be fast, and GCaMP sensors lack the temporal resolution to detect such rapid kinetics. The dissociation rate constant for GCaMP2.2Low (≈6 s −1 ; Online Figure 4B and 4C).
Mean data confirm that the inhibition of SR and sarcolemmal Ca 2+ fluxes in the cleft produces a significantly larger decline in the fluorescence of GCaMP2. Figure 4D ). This indicates that there is indeed a standing [Ca 2+ ] i gradient during diastole between the junctional cleft and the bulk cytosol. Assuming that diastolic [Ca 2+ ] Bulk =100 nmol/L (before tetracaine, 0Na + /0Ca 2+ ) and using data in Figure 1E , we calculated that diastolic [Ca 2+ ] Cleft is 194±28 nmol/L.
Another way of reducing diastolic SR Ca 2+ leak is to block SERCA with thapsigargin ( Figure 5A ). SERCA inhibition slowly unloads the SR, which is paralleled by a slow decrease in SR Ca 2+ leak. 33 As expected, with 10 µmol/L thapsigargin and 0Na + /0 Ca 2+ solution, the fluorescence signal in myocytes expressing either GCaMP2.2 or GCaMP2.2-FKBP12.6 declined more slowly, reaching a new steady state in ≈10 minutes ( Figure 5B) Figure 5C ). The overall decline in [Ca 2+ ] i was larger for thapsigargin versus tetracaine (presumably because of longer time in Ca 2+ -free solution), but the difference between cleft and bulk was similar for both methods (−ΔF/F 0 =0.36 versus 0.42).
To assess the relative contribution of the SR and sarcolemmal Ca 2+ fluxes to Ca 2+ entry into the cleft, we did separate experiments where only sarcolemmal Ca 2+ fluxes are blocked (0Na + /0 Ca 2+ solution). In this case, the decrease in the sensor fluorescence was similar for the FKBP12.6-tagged and the untagged sensor (−ΔF/F 0 =0.22±0.03 for GCaMP2.2-FKBP12.6 versus 0.17±0.02 for GCaMP2.2; Figure 5C ). In contrast, inhibition of SR Ca 2+ leak alone resulted in a significantly larger drop in the GCaMP2.2-FKBP12.6 fluorescence versus the untagged sensor (−ΔF/ F 0 =0.55±0.11 versus 0.24±0.07; Figure 5C ). These results indicate that most of the Ca 2+ entering the junctional cleft during diastole comes from the SR and SR Ca 2+ leak is the main factor in setting a diastolic [Ca 2+ ] i gradient between the cleft and the bulk cytosol.
Discussion
In many cell types, [Ca 2+ ] i is regulated and signals differently in various subcellular microdomains, which greatly enhances its versatility as a secondary messenger. Recognition of such subcellular regulation stimulated us to develop methods for measuring local [Ca 2+ ] i in microdomains. Here, we attached the genetically encoded Ca 2+ sensor GCaMP2.2 and a newly developed lower Ca 2+ affinity variant GCaMP2.2Low to the N terminus of FKBP12.6 to construct novel Ca 2+ sensors that bind specifically to RyRs. Our data indicate that GCaMP2.2-FKBP12.6 and GCaMP2.2Low-FKBP12.6 have a high affinity and selectivity for RyRs although slightly reduced when compared with untagged FKBP12.6. In cardiac myocytes, RyRs are localized predominantly in the junctional SR membrane, where the SR comes into close proximity of the external sarcolemma (the dyads). Because of this specific targeting, the FBP12. ] at nonjunctional RyRs may also be relevant, even if less influential on sarcolemmal currents. The adenoviral expression of GCaMP sensors in cardiac myocytes could risk alteration of dyad structure or function. Although cleft dimensions were not directly measured (eg, via electron microscopy), the FKBP12.6-targeted sensors are highly localized along T-tubules (of which ≈50% are in dyads in rat myocytes) 6 and normal synchronous transverse activation during ECC was maintained (Online Figure IV) . Therefore, we assume that the ultrastructure of the junctional cleft was not appreciably altered by the experimental conditions. FKBP12.6-GCaMP2.2 also has to be studied in a practical range of protein expression. If one waits too long or transfects too aggressively, one can express enough FKBP12.6-targeted protein to more than saturate the ≈1 µmol/L of RyR-binding sites. In that case, the excess sensor will not be effectively targeted. Any amount of untargeted GCaMP2. Figure 4E ), the characteristics of GCaMP2.2Low and GCaMP2.2Low-FKBP response to Ca 2+ in myocytes ( Figure 1E ), and the Ca 2+ transient amplitude ( Figure 3C) -dependent inactivation) and alter RyR gating to increase their activity by direct RyR activation and also indirectly via activation of CaMKII followed by CaMKII-dependent RyR phosphorylation. 39 Increased RyR opening leads to a larger SR Ca 2+ leak
